share_log

凯因科技(688687.SH):暂未布局血小板增高症领域

Kain Technology (688687.SH): has not yet entered the field of thrombocytosis.

Gelonghui Finance ·  Jul 17 06:30

On July 17, Gelun Hui reported that Kaiyin Technology (688687.SH) announced on the investor interaction platform that the company has conducted three clinical trials for different indications with Pai Yi Sheng: treatment of low-replication chronic HBV infection, shingles, and hepatic epithelioid hemangioendothelioma indications. Currently, all projects are steadily moving forward according to plan, and there is no layout of the thrombocytosis field. Please pay attention to public information for follow-up research and development of this product.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment